63 related articles for article (PubMed ID: 23379025)
1. Promising compound targets mitochondria in Huntington's disease.
Parks L
Future Med Chem; 2013 Jan; 5(1):18. PubMed ID: 23379025
[No Abstract] [Full Text] [Related]
2. 4-hydroxy tempo improves mitochondrial and neurobehavioral deficits in experimental model of Huntington's disease.
Sandhir R; Mahajan N; Mehrotra A; Aggarwal A; Sunkaria A
Synapse; 2015 Mar; 69(3):128-38. PubMed ID: 25482019
[TBL] [Abstract][Full Text] [Related]
3. Targeting of XJB-5-131 to mitochondria suppresses oxidative DNA damage and motor decline in a mouse model of Huntington's disease.
Xun Z; Rivera-Sánchez S; Ayala-Peña S; Lim J; Budworth H; Skoda EM; Robbins PD; Niedernhofer LJ; Wipf P; McMurray CT
Cell Rep; 2012 Nov; 2(5):1137-42. PubMed ID: 23122961
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial targeting of XJB-5-131 attenuates or improves pathophysiology in HdhQ150 animals with well-developed disease phenotypes.
Polyzos A; Holt A; Brown C; Cosme C; Wipf P; Gomez-Marin A; Castro MR; Ayala-Peña S; McMurray CT
Hum Mol Genet; 2016 May; 25(9):1792-802. PubMed ID: 26908614
[TBL] [Abstract][Full Text] [Related]
5. Hemigramicidin-TEMPO conjugates: novel mitochondria-targeted anti-oxidants.
Fink MP; Macias CA; Xiao J; Tyurina YY; Jiang J; Belikova N; Delude RL; Greenberger JS; Kagan VE; Wipf P
Biochem Pharmacol; 2007 Sep; 74(6):801-9. PubMed ID: 17601494
[TBL] [Abstract][Full Text] [Related]
6. Hope for Huntington's disease? A novel approach for disease modification.
Tunc S; Capetian P; Münchau A
Mov Disord; 2014 Aug; 29(9):1117. PubMed ID: 24909788
[No Abstract] [Full Text] [Related]
7. Novel mitochondria-localizing TEMPO derivative for measurement of cellular oxidative stress in mitochondria.
Ban S; Nakagawa H; Suzuki T; Miyata N
Bioorg Med Chem Lett; 2007 Apr; 17(7):2055-8. PubMed ID: 17275296
[TBL] [Abstract][Full Text] [Related]
8. N-Acetylcysteine reverses mitochondrial dysfunctions and behavioral abnormalities in 3-nitropropionic acid-induced Huntington's disease.
Sandhir R; Sood A; Mehrotra A; Kamboj SS
Neurodegener Dis; 2012; 9(3):145-57. PubMed ID: 22327485
[TBL] [Abstract][Full Text] [Related]
9. Animal models of Huntington's disease.
Gárdián G
Ideggyogy Sz; 2006 Nov; 59(11-12):396-9. PubMed ID: 17203874
[TBL] [Abstract][Full Text] [Related]
10. Protective effect of rivastigmine against 3-nitropropionic acid-induced Huntington's disease like symptoms: possible behavioural, biochemical and cellular alterations.
Kumar P; Kumar A
Eur J Pharmacol; 2009 Aug; 615(1-3):91-101. PubMed ID: 19445928
[TBL] [Abstract][Full Text] [Related]
11. A Double-Pronged Sword: XJB-5-131 Is a Suppressor of Somatic Instability and Toxicity in Huntington's Disease.
Wipf P; Polyzos AA; McMurray CT
J Huntingtons Dis; 2022; 11(1):3-15. PubMed ID: 34924397
[TBL] [Abstract][Full Text] [Related]
12. Minocycline is protective in a mouse model of Huntington's disease.
Hersch S; Fink K; Vonsattel JP; Friedlander RM
Ann Neurol; 2003 Dec; 54(6):841; author reply 842-3. PubMed ID: 14681897
[No Abstract] [Full Text] [Related]
13. Experimental therapeutics in transgenic mouse models of Huntington's disease.
Beal MF; Ferrante RJ
Nat Rev Neurosci; 2004 May; 5(5):373-84. PubMed ID: 15100720
[No Abstract] [Full Text] [Related]
14. Essential fatty acids in Huntington's disease.
Das UN; Vaddadi KS
Nutrition; 2004 Oct; 20(10):942-7. PubMed ID: 15474886
[TBL] [Abstract][Full Text] [Related]
15. Minocycline is not beneficial in a phenotypic mouse model of Huntington's disease.
Diguet E; Rouland R; Tison F
Ann Neurol; 2003 Dec; 54(6):841-2. PubMed ID: 14681898
[No Abstract] [Full Text] [Related]
16. Nortriptyline delays disease onset in models of chronic neurodegeneration.
Wang H; Guan Y; Wang X; Smith K; Cormier K; Zhu S; Stavrovskaya IG; Huo C; Ferrante RJ; Kristal BS; Friedlander RM
Eur J Neurosci; 2007 Aug; 26(3):633-41. PubMed ID: 17686041
[TBL] [Abstract][Full Text] [Related]
17. Role of tetrabenazine for Huntington's disease-associated chorea.
Poon LH; Kang GA; Lee AJ
Ann Pharmacother; 2010 Jun; 44(6):1080-9. PubMed ID: 20442355
[TBL] [Abstract][Full Text] [Related]
18. Genome-scale study of Huntington's disease identifies potential drug targets.
Pharmacogenomics; 2013 Jan; 14(2):123. PubMed ID: 23327572
[No Abstract] [Full Text] [Related]
19. Huntington's disease: which drugs might help patients?
Hannan AJ
IDrugs; 2004 Apr; 7(4):351-8. PubMed ID: 15057641
[TBL] [Abstract][Full Text] [Related]
20. Protective effect of hesperidin and naringin against 3-nitropropionic acid induced Huntington's like symptoms in rats: possible role of nitric oxide.
Kumar P; Kumar A
Behav Brain Res; 2010 Jan; 206(1):38-46. PubMed ID: 19716383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
